Developmental-stage-dependent transcriptional response to leukaemic oncogene expression.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26018585.
- Also identified by DOI 10.1038/ncomms8203 and PMC identifier 4458875.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Acute myeloid leukaemia (AML) is characterized by a block in myeloid differentiation the stage of which is dependent on the nature of the transforming oncogene and the developmental stage of the oncogenic hit. This is also true for the t(8;21) translocation that gives rise to the RUNX1-ETO fusion protein and initiates the most common form of human AML. Here we study the differentiation of mouse embryonic stem cells expressing an inducible RUNX1-ETO gene into blood cells as a model, combined with genome-wide analyses of transcription factor binding and gene expression. RUNX1-ETO interferes with both the activating and repressive function of its normal counterpart, RUNX1, at early and late stages of blood cell development. However, the response of the transcriptional network to RUNX1-ETO expression is developmental stage specific, highlighting the molecular mechanisms determining specific target cell expansion after an oncogenic hit.
Medical subject headings
- Core Binding Factor Alpha 2 Subunit
- DNA-Binding Proteins
- Gene Expression Regulation, Developmental
- Gene Expression Regulation, Neoplastic
- Hematopoiesis
- Mouse Embryonic Stem Cells
- Oncogene Proteins, Fusion
- Proto-Oncogene Proteins
- RNA, Messenger
- Transcription Factors